BioMarin Pharmaceutical, Inc. – FDA 483, Apr 17, 2014

A comprehensive 150-300 word summary of the FDA 483 document, specifically encompassing pages 12 through 21, cannot be generated as the textual content of these pages was not provided. To create an accurate and professional summary, critical information such as the company name, specific inspection dates, identified main violations or issues, the relevant regulatory framework under which the observations were made, and any implicitly or explicitly required actions would need to be extracted directly from the document's text. Without access to the actual content of the FDA 483 document, it is impossible to identify these key elements and synthesize a concise yet informative overview as requested. The request specifies using professional language without regulatory jargon, which further necessitates direct engagement with the document's content to ensure factual accuracy and appropriate phrasing.